Submitted by Anonymous (not verified) on 7 August 2023 - 14:51
Human medicines European public assessment report (EPAR): Camzyos, mavacamten, Cardiomyopathy, Hypertrophic, Date of authorisation: 26/06/2023, Revision: 1, Status: Authorised
Source: